Start:
September 2014
End:
August 2015
Enrollment:
64
This Phase I study will investigate the safety, tolerability, and pharmacokinetics of the experimental drug SUVN-G3031 in healthy male subjects.
Minimum Age: 18 Years
Maximum Age: 45 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Suven Life Sciences Ltd.
Source: ClinicalTrials.gov ID: NCT02342041
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health